Log In
Print
BCIQ
Print
Print this Print this
 

ODM-201

  Manage Alerts
Collapse Summary General Information
Company Orion Corp.
DescriptionOral androgen receptor inhibitor
Molecular Target Androgen receptor
Mechanism of ActionAndrogen receptor inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC); Treat non-metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation
Partner Bayer AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$68.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today